@FinnStockinger The Question is how much risk are you willing to take? $DRTS offers massive upside while significantly de-risking its clinical profile following the February 2026 Shonin marketing approval in Japan.
English
Jesse613
82 posts
The "Multibagger" List is in.
Now, how do we find the REAL winner?
You guys delivered some incredible alpha.
Here’s a snapshot of the tickers mentioned by the community so far:
$NIXX | $FPS | $ATOM | $UAN | $AEHR | $LWLG | $M7U | $LPKF | $IQE | $KULR | $DRTS | $OSS | $SIDU | $SLOIF
But let’s be real:
Buying everything on this list is a recipe for mediocrity.
Diversification is a hedge against ignorance, but concentration is how you build real wealth.
If you want a 10x return, you can't just follow the crowd. You need a filter.
So, I’m asking you:
How do YOU pick the "The One"?
What is your personal filter for a 10x play?
Or do you have another "dark horse" ticker that belongs on this list?
The discussion continues below. Share your process. 👇
Finn Stockinger@FinnStockinger
Time to find the NEXT 10x together. 🚀 Yesterday, I shared my conviction plays: $SATL, $KULR, and $IQE. My strategy is simple: look where the crowd isn’t looking yet. Now, I want to hear from YOU. We have an incredible community of alpha seekers here – let’s use it. Share this post with the entire community, let's do this together! Rules of the game: 1️⃣ Drop your pick for the next multibagger in the comments. 2️⃣ Use $TICKER + a short brief (Why is this an asymmetric play?). 3️⃣ You have 24 hours. What’s next?I will gather all the data, analyze the sentiment, and publish a "Community Alpha Report." The most-voted tickers will get their own deep-dive analysis posts from me. Let’s find the next "hidden gem" before the market wakes up. 💎 Share post to whole communit Start below! 👇
English
Jesse613 리트윗함
JUST IN: Alpha Tau (NASDAQ: $DRTS) to advance Pancreatic Cancer trial in Japan.
Following the marketing approval for their Alpha DaRT treatment in H&N Cancer, and the amazing results for Pancreatic Cancer in other countries, DRTS is set to start the trial via their Japanese partner Hekabio.
English
@AlphaTauInsight 100% response rate and no serious side effects. outstanding!
English
$DRTS CFO ahead of the several cancer trial readouts expected this year: “Last trial we read out we saw 100% complete response rate, every tumor disappeared of course, and we saw no serious side effects”
English
Jesse613 리트윗함
March Madness for biotech. 🧬
Most companies have a story.
Very few survive execution.
Alpha Tau Medical ($DRTS):
👉 Alpha DaRT = targeted alpha radiation inside tumors
👉 Early signals across multiple solid tumors
👉 Different approach vs traditional radiopharma
But here’s the game:
Story gets you in.
Execution keeps you alive.
High risk. Early stage.
But if the data hits → this moves fast.
Watching closely.
$DRTS #Biotech #qbri #CancerResearch #QuietBull
English
@AlphaTauInsight He is very reserved usually in his statements, hearing him like this, this is very exciting.
English
Jesse613 리트윗함
$DRTS CFO: “I expect looking at a very different company than where we are today. Just given what we expect to happen this year in our pivotal, brain cancer and pancreatic cancer studies, all really coming to a head.”
English
Jesse613 리트윗함
“Q2 catalysts success could drive 2-3x returns”
Dr. Elena Voss, Senior Biotech Equity Analyst, believes $DRTS is a “high-reward biotech with tangible de-risking milestones ahead.”
English
Jesse613 리트윗함
$DRTS great opportunity to participate in a groundbreaking cancer treatment. #cancer
Alpha Tau Insight@AlphaTauInsight
NEW: Alpha Tau Medical (NASDAQ: $DRTS) March 2026 Investor Presentation Highlights: - Upcoming catalysts - Massive potential TAM - FDA relationship - Keytruda combination trial - Manufacturing and Finances
English
Jesse613 리트윗함
$DRTS is not just for mice, it could save your mother.
English
Jesse613 리트윗함
“I’m cancer free thanks to $DRTS."
With hundreds of successfully treated patients worldwide, this FDA Breakthrough Device is a smarter way to treat cancer. Now approved in Japan with many upcoming catalysts.
English
Jesse613 리트윗함
״בעזרת הטיפול הזה, קיבלתי את איכות החיים המלאה שהייתה לי לפני שחליתי, מלאה אני מתכוון 100%״
לוחם השייטת לשעבר שנרפא מסרטן בזכות הטיפול של של חברת אלפא תאו $DRTS, מספר על ההחלטה ששינתה את חייו.
עברית
Jesse613 리트윗함
Citi and H.C. Wainwright raise price targets on $DRTS to $9 and $12.
Analysts say Japan’s approval validates the platform, de-risks U.S. progress, and is leading to partnership opportunities.
Upcoming catalysts include Phase 3 completion, Pancreatic and GBM trials, the Keytruda combination study, and more.
English
Jesse613 리트윗함
JUST IN: $DRTS to share results from first GBM patients.
Alpha Tau will hold an initial safety readout this coming quarter for the first three patients treated, followed by completion of patient recruitment for their FDA Recurrent Glioblastoma trial.
English
Jesse613 리트윗함
Connie, 71, after being treated by $DRTS: “I haven’t had any side effects. The cancer was not there, the Alpha DaRT seeds killed the cancer cells. That to me was just a miracle”
English
Jesse613 리트윗함
A trial combining Alpha DaRT by $DRTS and Keytruda (the #1 selling drug in the world) by Merck has shown promising results!
Alpha DaRT has significantly improved the results (19%->100% response rate) showing potential systemic and metastatic effects beyond the local treatment.
English
Jesse613 리트윗함
$DRTS's clinical, regulatory and commercial achievements for their revolutionary cancer treatment:
- FDA Breakthrough Device Designation
- FDA TAP program inclusion
- FDA MDSAP certification
- PMDA approval in Japan
- FDA PHASE 3 completion in Q1 2026
- FDA IDE’s for five cancers and counting
- FDA approval for commercial factory in the US, with other factories built and more in planing
- 100% tumor response rate in early FDA trials
- Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc…
- Activates immune system
- 55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…)
- Patents, IP and more…
English
Jesse613 리트윗함
After securing the PMDA marketing approval, these are the upcoming catalysts for $DRTS:
- Completing Phase 3 cSCC in Q1
- Completing Pancreas trial in H1
- Completing GBM trial
All three will be sharing results this year.
- Combination trial with Keytruda (the #1 selling drug in the world)
- Strategic Partnerships
- Commercialization
- Manufacturing
- New US trials (Prostste, H&N)
- 55+ Clinical sites worldwide treating many different indications including Lungs, Breast, Liver and all
- Conferences and Presentations
- And more!
English
Jesse613 리트윗함
Alpha Tau partners in Japan: “We have secured a location to build a manufacturing facility (in Japan) … there will be a point where the volume of supply is really gonna require us to have in-country manufacturing.” $DRTS
English
Jesse613 리트윗함
“The first time ever”: $DRTS Japanese partner, HekaBio CEO Rob Claar, explains why the Alpha Tau approval by the PMDA is an historic event
English
Jesse613 리트윗함
